EU IVDR Trend Reporting under Article 83: Methods, Thresholds and Observation Periods

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Article 83(1) requires manufacturers to report, through the electronic system referred to in Article 87, two kinds of statistically significant trends. The first covers events which do not constitute a serious incident but might lead to significant changes in the benefit-risk analysis of Annex I, Sections 1 and 5, and which have resulted or may result in an unacceptable risk to the health and safety of patients, users or other persons, where the frequency or severity of such events increases statistically significantly. The second covers a statistically significant increase in expected erroneous results relative to the established performance of the device, assessed against Annex I, Sections 9.1(a) and (b), and documented in the technical documentation and product information. Trend reporting is thus the designated channel for deterioration that is visible across a data set rather than in a single incident, and it applies alongside, not instead of, the Article 82 vigilance obligations. Together the two articles cover the full spectrum of adverse performance signals an IVD can produce.

2. Legal basis

Regulation / documentProvisionDatesSource
Regulation (EU) 2017/746 (IVDR)Articles 83(1) and (2) (trend reporting; competent authorities may carry out their own assessment and require measures to be taken)Adopted 2017-04-05; applicable 2022-05-26EUR-Lex
Same regulationArticle 82(1)(a) (expected erroneous results are excluded from serious incident reporting); Article 79 (PMS plan); Article 87 (electronic system for vigilance and post-market surveillance); Annex I, Sections 1, 5 and 9.12017-04-05EUR-Lex

3. Expert insights

Insight 1: Article 83 sets no fixed number of days, and that is its key difference from Article 82.

The text of Article 83 simply requires that reports be made by means of the electronic system; it does not impose a fixed deadline of the 15-day, 2-day or 10-day kind found in Article 82. Statements commonly encountered in the market that trend reports are also due within 15 days have no basis in the legal text, and this series does not adopt them. The rhythm of trend reporting is instead governed by the methods and observation periods defined in the PMS plan under Article 79, read together with the second subparagraph of Article 83(1). Manufacturers who mistakenly apply a 15-day clock to every trend signal distort both their internal workload and their authority communications.

Insight 2: The assessment methodology must be defined in the PMS plan in advance.

The second subparagraph of Article 83(1) requires the PMS plan to describe how such events will be managed, the methods used to establish any statistically significant increase in the frequency or severity of events, as well as any change in device performance, and the observation period. In other words, the meaning of statistically significant is a threshold defined by the manufacturer in the plan, in a form that a competent authority can verify, not an explanation invented after the data have been reviewed. A defensible definition states the baseline, the statistical test or rule applied, the denominator, and the window over which the comparison is made. Defining these parameters while the data are still neutral also protects the manufacturer from any later suggestion that thresholds were tuned to avoid reporting.

Insight 3: Competent authorities can turn a trend report back into mandatory action.

Article 83(2) allows competent authorities to carry out their own assessment of the trend report and to require the manufacturer to take appropriate measures under this Regulation to protect public health and patient safety. Each authority must inform the Commission, the other competent authorities and the notified body which issued the certificate of its assessment and of the measures required. A trend report therefore enters the regulatory arena directly, rather than remaining an internal record, and the quality of the analysis submitted will determine whether the authority accepts the manufacturer’s own assessment or imposes its own view of the necessary measures. Submitting a well-documented analysis with proposed measures, where any are warranted, is therefore the most effective way to keep control of the follow-up.

Insight 4: Trend reporting and serious incident reporting complement each other rather than overlap.

Article 82(1)(a) excludes from serious incident reporting those incidents involving expected erroneous results that are explicitly documented and quantified in the product information and technical documentation and are subject to trend reporting under Article 83. The assessment order should therefore be: first, determine whether the event constitutes a serious incident (if yes, apply Article 82); second, if the event falls within the expected erroneous results, determine whether a statistically significant increase has occurred (if yes, apply Article 83). Keeping this sequence explicit in the procedure prevents both double reporting and silent gaps where an event is reported on neither channel.

4. Practical recommendations

  1. Define in the PMS plan, for each event type, the baseline, the statistical method and the observation period, and re-validate these definitions as the product and data volumes evolve.
  2. Write the list of expected erroneous results, quantified, into the product information and technical documentation, as the evidentiary basis for the exclusion under Article 82(1)(a).
  3. Establish a channel-allocation process that decides between trend reporting and serious incident reporting for every qualifying event, and record the rationale for each decision.
  4. When a trend report is issued, assess in the same cycle whether corrective measures under Article 10(11) and a field safety corrective action under Article 82(8) are also required.
  5. Archive all communication with competent authorities and notified bodies relating to the trend report and any subsequent assessment (Article 83(2)).

5. Verification checklist

  • □ The PMS plan defines the trend assessment method, thresholds and observation period (Article 83(1))
  • □ The list of expected erroneous results is documented in the product information and technical documentation (Article 82(1)(a))
  • □ A channel-allocation process between trend reports and serious incident reports is established
  • □ Reports are submitted through the Article 87 electronic system (Article 83(1))
  • □ After reporting, the need for corrective measures and an FSCA has been assessed (Articles 10(11) and 82(8))
  • □ Communication records with competent authorities and notified bodies are archived (Article 83(2))

Legal information verified as of 29 October 2026.

GRZAN supports IVD manufacturers on the EU market with statistical trend governance under the IVDR: defining baselines, thresholds and observation periods in the PMS plan, maintaining quantified expected erroneous result lists, running the channel-allocation process between Article 82 and Article 83, and managing authority follow-up after trend reports. For support with trend reporting and PMPF data analysis, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail